Mathieu, C., Rudofsky, G., Phillip, M., Araki, E., Lind, M., Arya, N., . . . Dandona, P. (2020). Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT‐2 study): 52‐week results from a randomized controlled trial. Diabetes Obes Metab.
Chicago Style CitationMathieu, Chantal, et al. "Long‐term Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT‐2 Study): 52‐week Results From a Randomized Controlled Trial." Diabetes Obes Metab 2020.
Cita MLAMathieu, Chantal, et al. "Long‐term Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT‐2 Study): 52‐week Results From a Randomized Controlled Trial." Diabetes Obes Metab 2020.